← Product Code [DIF](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIF) · K033404

# LIQUICHEK URINE TOXICOLOGY CONTROL (CONFIRMATORY SERIES) (K033404)

_Bio-Rad · DIF · Dec 12, 2003 · Clinical Toxicology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIF/K033404

## Device Facts

- **Applicant:** Bio-Rad
- **Product Code:** [DIF](/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIF.md)
- **Decision Date:** Dec 12, 2003
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.3280
- **Device Class:** Class 1
- **Review Panel:** Clinical Toxicology

## Indications for Use

Liquichek Urine Toxicology Control is intended for use as a quality control urine to monitor the performance of laboratory urine toxicology confirmatory procedures.

## Device Story

Liquichek Urine Toxicology Control is a liquid-form quality control material prepared from human urine; supplemented with drugs of abuse, metabolites, preservatives, and stabilizers. Used in clinical laboratories by laboratory personnel to monitor the performance of urine toxicology confirmatory procedures. The control provides a known reference point to verify the accuracy and precision of analytical testing methods. By comparing the laboratory's test results for the control against expected values, clinicians and laboratory staff ensure the reliability of patient test results, thereby supporting accurate clinical decision-making regarding drug screening and confirmation.

## Clinical Evidence

No clinical data provided. Substantial equivalence is supported by bench testing, specifically stability studies demonstrating that all analytes remain stable for 30 days when stored at 2 to 8°C and a shelf life of 3 years at 2 to 8°C.

## Technological Characteristics

Liquid-form human urine-based control material. Contains drugs of abuse, metabolites, preservatives, and stabilizers. Value assignment via gas chromatography. Stability testing conducted at 2-8 °C and -20 °C. No electronic, software, or energy-based components.

## Regulatory Identification

A clinical toxicology control material is a device intended to provide an estimation of the precision of a device test system and to detect and monitor systematic deviations from accuracy resulting from reagent or instrument defects. This generic type of device includes various single, and multi-analyte control materials.

## Predicate Devices

- Liquichek Urine Toxicology Control Levels C1, C2, C3, C4 ([K021384](/device/K021384.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
DEVICE ONLY TEMPLATE

A. 510(k) Number:
K033404

B. Analyte:
Urine Toxicology Control Material (Drug Mixture)

C. Type of Test:
Control Material

D. Applicant:
Bio-Rad Laboratories

E. Proprietary and Established Names:
Liquicheck Urine Toxicology Control (Level C1, C2, C3, C4, C2 low opiate and C3 low opiate).

F. Regulatory Information:
1. Regulation section:
21CFR862.3280
2. Classification:
Class I
3. Product Code:
DIF
4. Panel:
91

G. Intended Use:
1. Intended use(s):
2. Indication(s) for use:
Liquicheck Urine Urine Toxicology Controls are intended for use as a quality control urine to monitor the performance of laboratory urine toxicology confirmatory procedures..
3. Special condition for use statement(s):
4. Special instrument Requirements:

H. Device Description:
Liquicheck Qualitative Urine Toxicology Controls are prepared from human urine with added drugs of abuse and metabolites of drugs of abuse, preservatives, stabilizers and constituents of animal origin. They are in liquid form. They contain

{1}

Page 2 of 3

Amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, LSD, methadone, methaqualone, opiates, phencyclidine and propoxyphene propoxyphene. The specific drugs within each class are listed in the package insert. Approximate drug levels based on gravimetric and GC analyses are listed in the package insert. The controls are supplied at various levels, (Level C1, C2, C3, C4, C2 low opiate and C3 low opiate).

I. Substantial Equivalence Information:

1. Predicate device name(s):
Liquichek Urine Toxicology Control Levels C1, C2, C3, C4

2. Predicate K number(s):
K021384

3. Comparison with predicate:
This control material is similar in composition to the predicate device, except that the new device contains MDMA, MDA and MDEA in levels C2, C3 and C4.

J. Standard/Guidance Document Referenced (if applicable):

K. Test Principle:
N/A. This 510(k) describes control material only.

L. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:
N/A

b. Linearity/assay reportable range:
N/A

c. Traceability (controls, calibrators, or method):
Value assignment is based on the average of triplicate analyses of control solutions at 3 reference laboratories using gas chromatography. Approximate GC and gravimetric values are listed in the package insert. The manufacturer recommends that each laboratory using Liquichek controls should use these results only as a reference and establish its own parameters for precision.

Open vial stability at 2-8 °C is tested at 6 time points, the last of which (t_final) extends to 20% longer than the expiration date. Recovery of the sample tested at that time point is compared, by GCMS, to a freshly opened vial. Acceptance criteria are that t_final must be within +/- 10% of the T_zero value.

Real-time stability studies are ongoing. Acceptance criteria are defined as recovery values at each time point that are within +/- 10% of the values determined for vials stored at 2-8 or -20 °C.

{2}

Page 3 of 3

d. Detection limit:
N/A

e. Analytical specificity:
N/A

f. Assay cut-off:
N/A

2. Comparison studies:
a. Method comparison with predicate device:
N/A
b. Matrix comparison:
N/A

3. Clinical studies:
a. Clinical sensitivity:
N/A
b. Clinical specificity:
N/A
c. Other clinical supportive data (when a and b are not applicable):

4. Clinical cut-off:
N/A

5. Expected values/Reference range:
N/A

M. Conclusion:
I recommend that the Biorad Liquichek Urine Toxicology Controls are substantially equivalent to the predicate device.

---

**Source:** [https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIF/K033404](https://fda.innolitics.com/submissions/TX/subpart-d%E2%80%94clinical-toxicology-test-systems/DIF/K033404)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com